| Gene symbol | TMPRSS6 | Synonyms | IRIDA, MT2 | Type of gene | protein-coding |
| Chromosome | 22 | Map location | 22q12.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | transmembrane serine protease 6 | ||||
| GTO ID | GTC2258 |
| Trial ID | NCT04176653 |
| Disease | Non-Transfusion-Dependent Thalassemia | Myelodysplastic Syndrome |
| Altered gene | TMPRSS6 |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | SLN124 |
| Phase | Phase1 |
| Recruitment status | Withdrawn |
| Title | Phase 1b Single Ascending and Multiple Dose First-in-man Study in Adult Patients With Non-transfusion-dependent Beta-thalassaemia or Low Risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN124 |
| Year | 2019 |
| Country | Bulgaria|United Kingdom |
| Company sponsor | Silence Therapeutics plc |
| Other ID(s) | SLN124-001 |
| Vector information | |||
|
|||
| Cohort1: Placebo | |||||||||
|
|||||||||
| Cohort2: SLN124_dose level 1 | |||||||||
|
|||||||||
| Cohort3: SLN124_dose level 2 | |||||||||
|
|||||||||
| Cohort4: SLN124_dose level 3 | |||||||||
|
|||||||||
| Cohort5: SLN124_dose level 4 | |||||||||
|
|||||||||